PAPPA2 and non-small cell lung carcinoma: To identify whether PAPPA2 mutation was associated with the response to ICIs therapy, we integrated the mutational and clinical data of three NSCLC cohorts (Rizvi, Hellmann and Miao cohorts) and four SKCM cohorts (Synder, Allen, Riaz cohort and Hugo cohorts) to form the NSCLC and SKCM set, respectively.